Total Funding
11
Total FundingSeries C raised
Growth Score
pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
505638
BiPar Sciences is a pharmacological company developing PARP inhibitors as cancer therapies.
Charles Bradley, Ph.D.: Vice President, Clinical Development- Barry Sherman, M.D.: Executive Vice President, Development
About the Company
BiPar Sciences is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.
BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital,
PolyTechnos Venture Partners, Asset Management Company, and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.
On April 15th, 2009, French drug maker Sanofi-Aventis S.A. announced it was acquiring BiPar Sciences for up to $500 million.
